PALVELLA THERAPEUTICS, INC.
PVLA$1.43B
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaWAYNE14 employees
Drugs in Pipeline
4
Phase 3 Programs
3
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
PVLA News
Catalyst Timeline
0 upcoming, 1 past
No catalysts found.
Drug Pipeline
Vehicle
Pachyonychia Congenita
QTORIN 3.9% Rapamycin Anhydrous Gel
Microcystic Lymphatic Malformation
PTX-022
Pachyonychia Congenita
Vehicle comparator
BCCs in Gorlin Syndrome Patients
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Vehicle | Phase 3 | Pachyonychia Congenita | - | - |
QTORIN 3.9% Rapamycin Anhydrous Gel | Phase 3 | Microcystic Lymphatic Malformation | - | - |
PTX-022 | Phase 3 | Pachyonychia Congenita | - | - |
Vehicle comparator | Phase 2 | BCCs in Gorlin Syndrome Patients | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply